What This Bill Does
H. Res. 1371 is a nonbinding House resolution that supports a World Sickle Cell Awareness Day on June 19, 2026. It calls for greater public awareness of sickle cell disease, better newborn screening, more research, and broader access to treatments and preventive care. The resolution also urges federal agencies to work on equitable access to innovative therapies, including cell, gene, and gene-editing treatments, especially within Medicare and Medicaid. It does not create a new program or set aside funding, but it signals federal support for awareness and policy action.
- Supports a World Sickle Cell Awareness Day on June 19, 2026.
- Calls on HHS to develop global policy solutions and support newborn screening, therapeutic interventions, and support services.
- Encourages the President to form a Sickle Cell Disease Interagency Group with HHS, VA, NIH, FDA, and CMS.
- Supports removing barriers to equitable access to cell, gene, and gene-editing therapies in Medicare and Medicaid.
- Urges programs and activities to raise awareness of sickle cell traits, prevention, treatments, and patient services.
Who This Bill Affects
For most Americans, this resolution has little direct day-to-day effect because it does not create a new benefit, mandate, or funding stream. For people living with sickle cell disease or sickle cell trait, however, it could help sustain pressure for better newborn screening, more research, and more equitable access to advanced therapies through HHS, CMS, NIH, FDA, and Veterans Affairs.
See how this bill affects you — sign in for a personalized analysisWho Supports & Opposes This
- Patients with sickle cell disease and their families They are likely to support the resolution because it elevates a disease that often requires lifelong care, better screening, and faster access to new therapies. The call for equitable access in Medicare and Medicaid is especially important for patients who face high treatment costs and care barriers.
- Hematologists, pediatric specialists, and other clinicians who treat SCD Medical providers may back the resolution because it emphasizes newborn screening, research, and preventative care, all of which can improve outcomes when started early. The text also highlights the need for broader access to therapies that can reduce crises and complications.
- Public health and research advocates Advocates focused on health equity may support the resolution because it explicitly addresses disparities, global burden, and the need for empirical research. The mention of an interagency group could help coordinate federal efforts across multiple health agencies.
- Fiscal conservatives and limited-government advocates They may oppose it as a symbolic measure that can invite future spending commitments or agency coordination without a clear budget framework. Even though the resolution itself does not appropriate money, it pushes federal involvement across several departments.
- Critics of federal policy statements without implementation power Some lawmakers and constituents may see it as largely ceremonial because it does not change benefits, create a program, or mandate funding. They may prefer Congress to focus on binding legislation that directly lowers costs or expands access.
- Health policy analysts concerned about uneven access to expensive therapies Some observers may worry that calling for equitable access to cell and gene therapies could raise expectations faster than the health system can deliver. They may note that access in Medicare and Medicaid will depend on later coverage, pricing, and provider infrastructure decisions.
Key Implications
-
““supports the goals and ideals of ‘World Sickle Cell Awareness Day’””
This is a formal congressional endorsement, not a binding requirement. Its main effect is to signal priorities and encourage public attention rather than change law on its own.
-
““create global policy solutions aimed at providing support for the global community””
The resolution pushes HHS toward international and domestic coordination on sickle cell disease. That could influence future agency initiatives, but it does not itself set timelines or funding levels.
-
““eliminating barriers to equitable access to innovative SCD therapies””
This points directly at coverage and access problems for advanced treatments. For patients, the practical issue is whether cell, gene, and gene-editing therapies become reachable in Medicare and Medicaid without major administrative or cost barriers.
-
““form a Sickle Cell Disease Interagency Group””
The resolution wants multiple federal agencies to coordinate policy, including HHS, VA, NIH, FDA, and CMS. That could improve consistency across screening, research, approval, and coverage decisions if the recommendation is adopted.
-
““consider options… [that] address the bias that the population most affected by SCD continues to face””
This acknowledges that sickle cell care is not only a medical issue but also an equity issue. It implies future policy discussions should address disparities in treatment access and quality of care.
Latest Status
June 18, 2026
Referred to the House Committee on Energy and Commerce.
Related Bills
Take Action
Get more from BillBoard
Free tools to understand, respond to, and track this bill.
Ask AI about this billData sourced from api.congress.gov.